Media releases Keyword Search Clear 2018 2017 2016 2015 2014 2013 2012 2011 Published on: 22 December 2017 Roche and Ignyta reach definitive merger agreement Roche and Ignyta, Inc. today announced they have entered into a definitive merger agreement for Roche to fully acquire Ignyta at a price of US$ 27.00 per share in an all-cash transaction. This ... more Published on: 21 December 2017 FDA approves Roche’s Perjeta (pertuzumab) for adjuvant treatment of specific type of early breast cancer Roche today announced the US Food and Drug Administration (FDA) has approved Perjeta® (pertuzumab), in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen), for ... more Published on: 21 December 2017 European Commission approves Roche’s Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer Roche today announced that the European Commission (EC) has granted a marketing authorisation for Alecensa® (alectinib) as a monotherapy for the first-line treatment of adult patients with anaplastic ... more Published on: 12 December 2017 Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated chronic lymphocytic leukaemia Roche today announced the first results from the pivotal phase III MURANO study evaluating Venclexta™/Venclyxto™ (venetoclax) plus MabThera®/Rituxan® (rituximab) compared to bendamustine plus ... more Published on: 11 December 2017 Phase III IMmotion151 study showed Roche’s Tecentriq (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death for the initial treatment of certain people with advanced kidney cancer Roche today announced that the Phase III IMmotion151 study met its co-primary endpoint of investigator-assessed progression-free survival (PFS) and demonstrated that the combination of Tecentriq® ... more Published on: 10 December 2017 Phase II data showed Roche’s investigational polatuzumab vedotin plus bendamustine and MabThera/Rituxan (BR) increased complete response rates compared to BR alone in previously treated aggressive lymphoma Roche today announced positive results from the randomised phase II GO29365 study that compared polatuzumab vedotin in combination with bendamustine plus MabThera®/Rituxan® (rituximab) (BR) against ... more Published on: 9 December 2017 Roche’s Hemlibra continued to substantially reduce bleeds in people with haemophilia A with inhibitors Roche announced today that new data from the ongoing Hemlibra® (emicizumab) clinical development programme were presented at the 59th American Society of Hematology (ASH) Annual Meeting. more Published on: 7 December 2017 Roche’s Hemlibra every four weeks controlled bleeds in phase III study in haemophilia A Roche today announced positive interim results from the phase III HAVEN 4 study evaluating Hemlibra® (emicizumab) prophylaxis dosed once every four weeks in adults and adolescents (12 years of age or ... more Published on: 7 December 2017 Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent for people with a type of advanced lung cancer Roche today announced results from the positive, pivotal Phase III IMpower150 study of Tecentriq® (atezolizumab) and Avastin® (bevacizumab) plus chemotherapy (carboplatin and paclitaxel) in people ... more Published on: 4 December 2017 FDA approves Foundation Medicine’s FoundationOne CDx, the first pan-tumour comprehensive genomic profiling assay incorporating a broad range of companion diagnostics Roche announced today that the US Food and Drug Administration (FDA) has approved FoundationOne CDx™, Foundation Medicine’s comprehensive companion diagnostic assay for personalised oncology care. more Published on: 20 November 2017 Roche’s Hemlibra significantly reduced bleeds in phase III study in haemophilia A Roche today announced positive results from the phase III HAVEN 3 study evaluating Hemlibra® (emicizumab) in adults and adolescents (aged 12 years or older) with haemophilia A without inhibitors to ... more Published on: 20 November 2017 Phase III IMpower150 study showed Roche’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus chemotherapy significantly reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced lung cancer Roche today announced that the Phase III IMpower150 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ® (atezolizumab) and ... more Published on: 17 November 2017 Roche to acquire Viewics, Inc. to provide data-driven lab business analytics and add further digital capabilities along the laboratory value chain Roche today announced an agreement with Viewics, Inc., a privately held software company focused on laboratory business analytics. Under the agreement, Roche is acquiring all shares of the company. ... more Published on: 17 November 2017 FDA approves Roche’s Gazyva for previously untreated advanced follicular lymphoma Roche announced today that the US Food and Drug Administration (FDA) approved Gazyva® (obinutuzumab) in combination with chemotherapy, followed by Gazyva alone in those who responded, for people with ... more Published on: 16 November 2017 FDA approves Roche’s Hemlibra (emicizumab-kxwh) for haemophilia A with inhibitors Roche today announced that the US Food and Drug Administration (FDA) has approved Hemlibra® (emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults ... more Published on: 10 November 2017 Roche’s OCREVUS (ocrelizumab) gains positive CHMP opinion for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of OCREVUS for people with active relapsing forms of multiple sclerosis ... more Published on: 7 November 2017 FDA approves Zelboraf (vemurafenib) for Erdheim-Chester disease with BRAF V600 mutation Roche announced today that the US Food and Drug Administration (FDA) has approved Zelboraf® (vemurafenib) for Erdheim-Chester disease (ECD) with BRAF V600 mutation. ECD is a rare, serious blood ... more Published on: 7 November 2017 FDA approves Roche’s Alecensa (alectinib) as first-line treatment for people with specific type of lung cancer Roche today announced that the US Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for Alecensa® (alectinib) for the treatment of people with anaplastic ... more Published on: 1 November 2017 Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting Roche today announced that new data on its approved and investigational medicines for blood diseases will be presented at the 59th American Society of Hematology (ASH) Annual Meeting from 9 – 12 ... more Published on: 27 October 2017 New OCREVUS (ocrelizumab) data at ECTRIMS advance clinical understanding of underlying progression in multiple sclerosis Roche announced today that new OCREVUS® (ocrelizumab) data are being presented at the 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) – Americas Committee for ... more Published on: 24 October 2017 Roche recognised as a global leader for sustainable water management For the first time, Roche has been identified as a global leader for its actions to manage water more sustainably. CDP, the non-profit global environmental disclosure platform, has awarded Roche a ... more Published on: 19 October 2017 Roche reports strong sales growth in the first nine months of 2017 Group sales rose 5% to CHF 39.4 billion. Sales in the Pharmaceuticals Division increased 5% to CHF 30.6 billion. more Published on: 16 October 2017 Roche to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive forms of multiple sclerosis at ECTRIMS Roche announced today that new data on OCREVUS® (ocrelizumab) in people with relapsing and primary progressive forms of multiple sclerosis (MS) will be presented during the 7th Joint European ... more Published on: 13 October 2017 CHMP recommends EU approval of Roche’s Alecensa (alectinib) as a first-line treatment for people with ALK-positive NSCLC Roche announced today that the European Union’s (EU) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Alecensa® (alectinib) as a ... more Published on: 6 October 2017 FDA approves Roche cobas Zika as first commercially-available donor screening test for Zika virus Roche announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for the cobas® Zika test for use on the cobas 6800/8800 Systems. more Published on: 3 October 2017 Roche launches NAVIFY Tumor Board solution to provide decision support to oncology care teams Roche, today announced the launch of the NAVIFY Tumor Board solution, a clinical workflow and decision support software that optimises decision-making for cancer patient case reviews in tumor boards, ... more Published on: 29 September 2017 FDA grants Priority Review for Roche’s Perjeta (pertuzumab) for adjuvant treatment of HER2-positive early breast cancer Roche today announced the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Perjeta® (pertuzumab), in ... more Published on: 28 September 2017 Roche’s OCREVUS (ocrelizumab) approved in Switzerland for primary progressive and relapsing forms of multiple sclerosis Roche announced today that the Swiss agency for the authorisation and supervision of therapeutic products (Swissmedic) has granted authorisation of OCREVUS® (ocrelizumab) for the treatment of adult ... more Published on: 22 September 2017 Roche receives EU approval of TECENTRIQ® (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer Roche today announced that the European Commission (EC) has granted a marketing authorisation for TECENTRIQ (atezolizumab) as a monotherapy for the treatment of people with locally advanced or ... more Published on: 22 September 2017 Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma Roche announced today that the European Commission has approved Gazyvaro® (obinutuzumab) in combination with chemotherapy, followed by Gazyvaro maintenance in people achieving a response, as a new ... more Published on: 22 September 2017 Roche receives European approval for Actemra /RoActemra in giant cell arteritis Roche announced today that the European Commission (EC) has approved Actemra®/RoActemra® (tocilizumab) for the treatment of giant cell arteritis (GCA), a chronic and potentially life-threatening ... more Published on: 18 September 2017 Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan Roche announced today that the phase III MURANO study, which evaluated Venclexta®/Venclyxto® (venetoclax) in combination with MabThera®/Rituxan® (rituximab) in people with relapsed or refractory ... more Published on: 13 September 2017 Results of a six-month study combining Roche’s Esbriet with nintedanib in patients with IPF presented at ERS Roche today announced results of a six month study combining Esbriet (pirfenidone) and nintedanib treatment, showing a similar safety profile for the combination treatment to that expected for each ... more Published on: 11 September 2017 Roche announces phase III study results of Zelboraf for adjuvant treatment of BRAF V600 mutation-positive melanoma Roche today announced data for the phase III BRIM8 study, which was designed to investigate the efficacy and safety of Zelboraf® (vemurafenib) in the adjuvant (after surgery) treatment of people with ... more Published on: 8 September 2017 Roche provides update on first lampalizumab phase III study for geographic atrophy, an advanced form of age-related macular degeneration Roche today announced that the primary endpoint has not been met in Spectri, the first of two phase III studies evaluating the safety and efficacy of lampalizumab, an investigational medicine for the ... more Published on: 8 September 2017 Roche announces progress in biomarker science in cancer immunotherapy at the European Society for Medical Oncology Congress Roche announced today that the first data on a novel blood-based assay, co-developed with Foundation Medicine (NASDAQ: FMI), will be presented during the European Society for Medical Oncology (ESMO) ... more Published on: 7 September 2017 Roche ranked again the most sustainable healthcare company in the Dow Jones Sustainability Indices For the ninth consecutive year, Roche has been recognised as Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry index of the Dow Jones Sustainability ... more Published on: 6 September 2017 Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer Roche today announced results from the global phase III ALUR study showing that Alecensa® significantly reduced the risk of disease worsening or death (progression-free survival, PFS) by 85% compared ... more Published on: 31 August 2017 Roche to present new data from its oncology portfolio at the 2017 European Society for Medical Oncology (ESMO) Congress Roche today announced that new results from a number of studies across 18 approved and investigational medicines will be presented during the European Society for Medical Oncology (ESMO) Congress ... more Published on: 30 August 2017 FDA approves Roche’s Actemra/RoActemra (tocilizumab) for the treatment of CAR T cell-induced cytokine release syndrome Roche announced today that the US Food and Drug Administration (FDA) has approved Actemra/RoActemra® (tocilizumab) intravenous injection for the treatment of chimeric antigen receptor (CAR) T ... more Published on: 24 August 2017 FDA grants Priority Review to Roche’s emicizumab for haemophilia A with inhibitors Roche today announced that the US Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) and granted Priority Review for emicizumab prophylaxis ... more Published on: 27 July 2017 Roche reports strong performance in the first half of 2017 Group sales increase 5% at constant exchange rates and in Swiss francs more Published on: 21 July 2017 Roche gains positive CHMP opinion for Actemra / RoActemra in giant cell arteritis Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of Actemra®/RoActemra® (tocilizumab) for the treatment of ... more Published on: 21 July 2017 CHMP recommends EU approval of Roche’s Gazyvaro for people with previously untreated advanced follicular lymphoma Roche announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Gazyvaro® (obinutuzumab) in combination with chemotherapy, followed by ... more Published on: 21 July 2017 CHMP recommends EU approval for Roche’s TECENTRIQ (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer Roche today announced that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for TECENTRIQ® (atezolizumab) as a monotherapy for the treatment of adults with ... more Published on: 17 July 2017 Roche’s OCREVUS (ocrelizumab) approved for relapsing and primary progressive multiple sclerosis in Australia Roche announced today that OCREVUS® (ocrelizumab) has been approved by the Australian Therapeutic Goods Administration (TGA) for the treatment of relapsing forms of multiple sclerosis (RMS) and ... more Published on: 10 July 2017 Positive phase III results for Roche’s emicizumab in haemophilia A published in The New England Journal of Medicine Roche today announced that data from HAVEN 1, a phase III study evaluating once-weekly subcutaneous emicizumab prophylaxis (preventative) in adults and adolescents with haemophilia A with inhibitors, ... more Published on: 3 July 2017 Roche expands cobas Liat PCR System menu with launch of cobas MRSA/SA test to target healthcare-associated infections Roche announced today the CE-IVD launch of the cobas® MRSA/SA nucleic acid test for use on the cobas® Liat® System for the qualitative detection and differentiation of methicillin-resistant ... more Published on: 30 June 2017 Roche acquires mySugr to form a leading open platform for digital diabetes management Roche and mySugr announced today that the two partners have signed an agreement under which Roche acquired all shares of mySugr GmbH. more Published on: 27 June 2017 Fewer pills, more flexibility in dosing: Roche’s new Esbriet tablet formulation approved in Europe for mild to moderate idiopathic pulmonary fibrosis (IPF) Roche today announced that the European Commission (EC) has approved a new tablet formulation of Esbriet® (pirfenidone) for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF), a ... more Published on: 26 June 2017 Roche’s emicizumab showed positive results in phase III studies (HAVEN 1 and HAVEN 2) in haemophilia A with inhibitors Roche today announced positive data from the primary analysis of the phase III HAVEN 1 study in adults and adolescents and interim analysis of the phase III HAVEN 2 study in children evaluating ... more Published on: 23 June 2017 Presentation confirms Venclexta/Venclyxto monotherapy benefit in certain patients with high-risk chronic lymphocytic leukaemia and its potential in other hard-to-treat blood cancers Roche today announced new data from multiple studies of Venclexta®/Venclyxto® (venetoclax), presented at the 22nd European Hematology Association (EHA) Annual Congress, 22-25 June, in Madrid. more Published on: 23 June 2017 Roche presents new data from GALLIUM study reinforcing clinical benefit of Gazyva/Gazyvaro in people with previously untreated follicular lymphoma Roche announced today that new data from additional analyses of the pivotal phase III GALLIUM study in people with previously untreated follicular lymphoma will be presented at the 22nd European ... more Published on: 23 June 2017 New data at EAN show Roche’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary progressive multiple sclerosis Roche announced today that new post-hoc analyses from the OCREVUS™ (ocrelizumab) Phase III clinical trial programme in people with relapsing and primary progressive forms of multiple sclerosis (RMS ... more Published on: 23 June 2017 FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers Roche announced today that the US Food and Drug Administration (FDA) approved Rituxan Hycela™ (rituximab and hyaluronidase human) for subcutaneous (under the skin) injection, for the treatment of ... more Published on: 14 June 2017 Roche’s employee-driven philanthropic campaign sets new record Today, Roche employees from 145 company sites in 70 countries participate in the 14th Roche Children’s Walk. more Published on: 5 June 2017 Phase III study showed Roche’s Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer Roche today announced that the phase III ALEX study showed Alecensa® (alectinib) significantly reduced the risk of disease worsening or death (progression-free survival, PFS) by more than half (53%) ... more Published on: 5 June 2017 APHINITY study shows Roche’s Perjeta-based regimen reduced the risk of invasive cancer returning compared to Herceptin and chemotherapy in HER2-positive early breast cancer Roche, the Breast International Group (BIG), Breast European Adjuvant Study Team (BrEAST) and Frontier Science Foundation (FS) today announced the Phase III APHINITY study showed adjuvant (after ... more Published on: 3 June 2017 Roche presents new data for TECENTRIQ® (atezolizumab) and updates from across its cancer immunotherapy development programme at ASCO 2017 Roche today announced that new data for TECENTRIQ and updates from across its extensive cancer immunotherapy clinical development programme will be presented during the American Society of Clinical ... more Published on: 24 May 2017 New data at ATS add to the body of evidence for Roche’s Esbriet (pirfenidone) in idiopathic pulmonary fibrosis (IPF) Roche today announced new retrospective data analyses for Esbriet® (pirfenidone) in idiopathic pulmonary fibrosis (IPF) that were presented at the American Thoracic Society (ATS) 2017 International ... more Published on: 23 May 2017 FDA approves Roche’s Actemra/RoActemra (tocilizumab) for giant cell arteritis Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Actemra®/RoActemra® (tocilizumab) ) subcutaneous injection for the treatment of GCA, a chronic and severe ... more Published on: 11 May 2017 Roche to present new data on personalised medicines and cancer immunotherapies at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting Roche today announced new data on 20 approved and investigational medicines will be presented during the American Society of Clinical Oncology (ASCO) Annual Meeting from 2 June to 6 June in Chicago, ... more Published on: 10 May 2017 Roche provides update on phase III study of TECENTRIQ® (atezolizumab) in people with previously treated advanced bladder cancer Roche today announced that the Phase III IMvigor211 study that evaluated TECENTRIQ® (atezolizumab) in people with locally advanced or metastatic urothelial cancer (mUC) whose disease progressed ... more Published on: 8 May 2017 Roche launches AVENIO ctDNA Analysis Kits for Oncology Research Roche today announced the global commercial launch of the AVENIO circulating tumor DNA (ctDNA) Analysis Kits, a portfolio of three next-generation sequencing (NGS) liquid biopsy assay kits for ... more Published on: 27 April 2017 Roche reports a good start in 2017 Group sales increase 4%1 at constant exchange rates and in Swiss francs. Pharmaceuticals Division sales up 3%, driven mainly by Tecentriq and Perjeta. Diagnostics Division sales grow 6%, primarily ... more Published on: 26 April 2017 New data at AAN reinforce clinical benefit of Roche's OCREVUS™ (ocrelizumab) for relapsing and primary progressive multiple sclerosis Roche announced today that new data from the OCREVUS™ (ocrelizumab) clinical trial programmes will be presented during the 69th American Academy of Neurology (AAN) Annual Meeting in Boston, ... more Published on: 19 April 2017 Roche to present new data at AAN reinforcing efficacy and safety of newly FDA-approved OCREVUS™ (ocrelizumab) in two types of multiple sclerosis Roche announced today that new data on OCREVUS™ (ocrelizumab) in people with relapsing forms of multiple sclerosis (RMS) and primary progressive MS (PPMS) will be presented during the 69th American ... more Published on: 18 April 2017 FDA approves Roche’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States Roche today announced that the US Food and Drug Administration (FDA) approved Lucentis® (ranibizumab injection) 0.3 mg for the monthly treatment of withal forms of diabetic retinopathy. more Published on: 18 April 2017 FDA grants Roche’s TECENTRIQ® (atezolizumab) accelerated approval as initial treatment for certain people with advanced bladder cancer Roche today announced that the US Food and Drug Administration (FDA) granted accelerated approval to TECENTRIQ® (atezolizumab) for the treatment of people with locally advanced or metastatic ... more Published on: 17 April 2017 Roche announces positive interim results for emicizumab in phase III study of children with haemophilia A Roche announced today interim results from the phase III HAVEN 2 study evaluating emicizumab prophylaxis in children less than 12 years of age with haemophilia A and inhibitors to factor VIII. more Published on: 10 April 2017 Phase III study shows Roche’s Alecensa was superior to crizotinib in a specific type of lung cancer Roche today announced that the global, randomised phase III ALEX study met its primary endpoint and showed that Alecensa® (alectinib) as an initial (first-line) treatment significantly reduced the ... more Published on: 5 April 2017 Improving consistency in the diagnosis of cervical pre-cancers: Roche CINtec Histology test receives FDA clearance Roche today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the CINtec® Histology test. more Published on: 3 April 2017 Roche launches cobas Liat PCR System with four assays into CE-markets Roche today announced the CE-IVD launch of the cobas® Liat® PCR System with four assays including first 20 minute real-time PCR nucleic acid test to detect Clostridium difficile (C. diff). more Published on: 3 April 2017 Phase III ALUR study supports the use of Roche’s Alecensa for people with advanced ALK-positive lung cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III ALUR study met its primary endpoint, demonstrating that Alecensa® (alectinib) significantly improved progression-free survival ... more Published on: 29 March 2017 FDA approves Roche’s OCREVUS™ (ocrelizumab) for relapsing and primary progressive forms of multiple sclerosis Roche announced today that the US Food and Drug Administration (FDA) approved OCREVUS™ (ocrelizumab) as the first and only medicine for both relapsing and primary progressive forms of multiple ... more Published on: 28 March 2017 Roche announces launch of cobas HPV on the cobas 6800/8800 Systems for cervical cancer screening in markets accepting the CE mark Roche announced today the CE-IVD launch of cobas® HPV for use on the cobas® 6800/8800 Systems for cervical cancer screening. more Published on: 14 March 2017 Roche Annual General Meeting 2017 Roche announced today that its shareholders approved all proposals of the Board of Directors at its ordinary Annual General Meeting (AGM). more Published on: 2 March 2017 Phase III APHINITY study shows Roche’s Perjeta® regimen helped people with an aggressive type of early breast cancer live longer without their disease returning compared to Herceptin® and chemotherapy Roche, the Breast International Group (BIG), Breast European Adjuvant Study Team (BrEAST) and Frontier Science Foundation (FS) today announced positive results from the phase III APHINITY study. more Published on: 21 February 2017 Roche receives EU approval of Alecensa (alectinib) for people with previously treated ALK-positive non-small cell lung cancer Roche announced today that the European Commission has granted a conditional marketing authorisation for Alecensa® (alectinib) as monotherapy for the treatment of adult patients with anaplastic ... more Published on: 18 February 2017 Phase II study supports potential for Roche’s TECENTRIQ (atezolizumab) plus Avastin (bevacizumab) for people with locally advanced or metastatic renal cell carcinoma Roche today announced encouraging results from the Phase II IMmotion150 study that compared TECENTRIQ® (atezolizumab) plus Avastin® (bevacizumab) and TECENTRIQ monotherapy to sunitinib alone in ... more Published on: 1 February 2017 Roche reports good results in 2016 Commenting on the Group’s results, Roche CEO Severin Schwan said: «I am pleased that we have again reached all our financial targets while our product portfolio has made significant progress ... more Published on: 23 January 2017 Roche enters a new era in haematology testing, with the launch of the new cobas m 511 analyser Roche announced today that its new, dedicated haematology testing solution, the cobas m 511 integrated haematology analyser, is now available for countries accepting the CE Mark. more Published on: 9 January 2017 FDA grants Roche’s cancer immunotherapy TECENTRIQ(atezolizumab) Priority Review in additional type of advanced bladder cancer Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for TECENTRIQ® ... more
Published on: 22 December 2017 Roche and Ignyta reach definitive merger agreement Roche and Ignyta, Inc. today announced they have entered into a definitive merger agreement for Roche to fully acquire Ignyta at a price of US$ 27.00 per share in an all-cash transaction. This ... more
Published on: 21 December 2017 FDA approves Roche’s Perjeta (pertuzumab) for adjuvant treatment of specific type of early breast cancer Roche today announced the US Food and Drug Administration (FDA) has approved Perjeta® (pertuzumab), in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen), for ... more
Published on: 21 December 2017 European Commission approves Roche’s Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer Roche today announced that the European Commission (EC) has granted a marketing authorisation for Alecensa® (alectinib) as a monotherapy for the first-line treatment of adult patients with anaplastic ... more
Published on: 12 December 2017 Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated chronic lymphocytic leukaemia Roche today announced the first results from the pivotal phase III MURANO study evaluating Venclexta™/Venclyxto™ (venetoclax) plus MabThera®/Rituxan® (rituximab) compared to bendamustine plus ... more
Published on: 11 December 2017 Phase III IMmotion151 study showed Roche’s Tecentriq (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death for the initial treatment of certain people with advanced kidney cancer Roche today announced that the Phase III IMmotion151 study met its co-primary endpoint of investigator-assessed progression-free survival (PFS) and demonstrated that the combination of Tecentriq® ... more
Published on: 10 December 2017 Phase II data showed Roche’s investigational polatuzumab vedotin plus bendamustine and MabThera/Rituxan (BR) increased complete response rates compared to BR alone in previously treated aggressive lymphoma Roche today announced positive results from the randomised phase II GO29365 study that compared polatuzumab vedotin in combination with bendamustine plus MabThera®/Rituxan® (rituximab) (BR) against ... more
Published on: 9 December 2017 Roche’s Hemlibra continued to substantially reduce bleeds in people with haemophilia A with inhibitors Roche announced today that new data from the ongoing Hemlibra® (emicizumab) clinical development programme were presented at the 59th American Society of Hematology (ASH) Annual Meeting. more
Published on: 7 December 2017 Roche’s Hemlibra every four weeks controlled bleeds in phase III study in haemophilia A Roche today announced positive interim results from the phase III HAVEN 4 study evaluating Hemlibra® (emicizumab) prophylaxis dosed once every four weeks in adults and adolescents (12 years of age or ... more
Published on: 7 December 2017 Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent for people with a type of advanced lung cancer Roche today announced results from the positive, pivotal Phase III IMpower150 study of Tecentriq® (atezolizumab) and Avastin® (bevacizumab) plus chemotherapy (carboplatin and paclitaxel) in people ... more
Published on: 4 December 2017 FDA approves Foundation Medicine’s FoundationOne CDx, the first pan-tumour comprehensive genomic profiling assay incorporating a broad range of companion diagnostics Roche announced today that the US Food and Drug Administration (FDA) has approved FoundationOne CDx™, Foundation Medicine’s comprehensive companion diagnostic assay for personalised oncology care. more
Published on: 20 November 2017 Roche’s Hemlibra significantly reduced bleeds in phase III study in haemophilia A Roche today announced positive results from the phase III HAVEN 3 study evaluating Hemlibra® (emicizumab) in adults and adolescents (aged 12 years or older) with haemophilia A without inhibitors to ... more
Published on: 20 November 2017 Phase III IMpower150 study showed Roche’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus chemotherapy significantly reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced lung cancer Roche today announced that the Phase III IMpower150 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ® (atezolizumab) and ... more
Published on: 17 November 2017 Roche to acquire Viewics, Inc. to provide data-driven lab business analytics and add further digital capabilities along the laboratory value chain Roche today announced an agreement with Viewics, Inc., a privately held software company focused on laboratory business analytics. Under the agreement, Roche is acquiring all shares of the company. ... more
Published on: 17 November 2017 FDA approves Roche’s Gazyva for previously untreated advanced follicular lymphoma Roche announced today that the US Food and Drug Administration (FDA) approved Gazyva® (obinutuzumab) in combination with chemotherapy, followed by Gazyva alone in those who responded, for people with ... more
Published on: 16 November 2017 FDA approves Roche’s Hemlibra (emicizumab-kxwh) for haemophilia A with inhibitors Roche today announced that the US Food and Drug Administration (FDA) has approved Hemlibra® (emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults ... more
Published on: 10 November 2017 Roche’s OCREVUS (ocrelizumab) gains positive CHMP opinion for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of OCREVUS for people with active relapsing forms of multiple sclerosis ... more
Published on: 7 November 2017 FDA approves Zelboraf (vemurafenib) for Erdheim-Chester disease with BRAF V600 mutation Roche announced today that the US Food and Drug Administration (FDA) has approved Zelboraf® (vemurafenib) for Erdheim-Chester disease (ECD) with BRAF V600 mutation. ECD is a rare, serious blood ... more
Published on: 7 November 2017 FDA approves Roche’s Alecensa (alectinib) as first-line treatment for people with specific type of lung cancer Roche today announced that the US Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for Alecensa® (alectinib) for the treatment of people with anaplastic ... more
Published on: 1 November 2017 Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting Roche today announced that new data on its approved and investigational medicines for blood diseases will be presented at the 59th American Society of Hematology (ASH) Annual Meeting from 9 – 12 ... more
Published on: 27 October 2017 New OCREVUS (ocrelizumab) data at ECTRIMS advance clinical understanding of underlying progression in multiple sclerosis Roche announced today that new OCREVUS® (ocrelizumab) data are being presented at the 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) – Americas Committee for ... more
Published on: 24 October 2017 Roche recognised as a global leader for sustainable water management For the first time, Roche has been identified as a global leader for its actions to manage water more sustainably. CDP, the non-profit global environmental disclosure platform, has awarded Roche a ... more
Published on: 19 October 2017 Roche reports strong sales growth in the first nine months of 2017 Group sales rose 5% to CHF 39.4 billion. Sales in the Pharmaceuticals Division increased 5% to CHF 30.6 billion. more
Published on: 16 October 2017 Roche to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive forms of multiple sclerosis at ECTRIMS Roche announced today that new data on OCREVUS® (ocrelizumab) in people with relapsing and primary progressive forms of multiple sclerosis (MS) will be presented during the 7th Joint European ... more
Published on: 13 October 2017 CHMP recommends EU approval of Roche’s Alecensa (alectinib) as a first-line treatment for people with ALK-positive NSCLC Roche announced today that the European Union’s (EU) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Alecensa® (alectinib) as a ... more
Published on: 6 October 2017 FDA approves Roche cobas Zika as first commercially-available donor screening test for Zika virus Roche announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for the cobas® Zika test for use on the cobas 6800/8800 Systems. more
Published on: 3 October 2017 Roche launches NAVIFY Tumor Board solution to provide decision support to oncology care teams Roche, today announced the launch of the NAVIFY Tumor Board solution, a clinical workflow and decision support software that optimises decision-making for cancer patient case reviews in tumor boards, ... more
Published on: 29 September 2017 FDA grants Priority Review for Roche’s Perjeta (pertuzumab) for adjuvant treatment of HER2-positive early breast cancer Roche today announced the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Perjeta® (pertuzumab), in ... more
Published on: 28 September 2017 Roche’s OCREVUS (ocrelizumab) approved in Switzerland for primary progressive and relapsing forms of multiple sclerosis Roche announced today that the Swiss agency for the authorisation and supervision of therapeutic products (Swissmedic) has granted authorisation of OCREVUS® (ocrelizumab) for the treatment of adult ... more
Published on: 22 September 2017 Roche receives EU approval of TECENTRIQ® (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer Roche today announced that the European Commission (EC) has granted a marketing authorisation for TECENTRIQ (atezolizumab) as a monotherapy for the treatment of people with locally advanced or ... more
Published on: 22 September 2017 Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma Roche announced today that the European Commission has approved Gazyvaro® (obinutuzumab) in combination with chemotherapy, followed by Gazyvaro maintenance in people achieving a response, as a new ... more
Published on: 22 September 2017 Roche receives European approval for Actemra /RoActemra in giant cell arteritis Roche announced today that the European Commission (EC) has approved Actemra®/RoActemra® (tocilizumab) for the treatment of giant cell arteritis (GCA), a chronic and potentially life-threatening ... more
Published on: 18 September 2017 Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan Roche announced today that the phase III MURANO study, which evaluated Venclexta®/Venclyxto® (venetoclax) in combination with MabThera®/Rituxan® (rituximab) in people with relapsed or refractory ... more
Published on: 13 September 2017 Results of a six-month study combining Roche’s Esbriet with nintedanib in patients with IPF presented at ERS Roche today announced results of a six month study combining Esbriet (pirfenidone) and nintedanib treatment, showing a similar safety profile for the combination treatment to that expected for each ... more
Published on: 11 September 2017 Roche announces phase III study results of Zelboraf for adjuvant treatment of BRAF V600 mutation-positive melanoma Roche today announced data for the phase III BRIM8 study, which was designed to investigate the efficacy and safety of Zelboraf® (vemurafenib) in the adjuvant (after surgery) treatment of people with ... more
Published on: 8 September 2017 Roche provides update on first lampalizumab phase III study for geographic atrophy, an advanced form of age-related macular degeneration Roche today announced that the primary endpoint has not been met in Spectri, the first of two phase III studies evaluating the safety and efficacy of lampalizumab, an investigational medicine for the ... more
Published on: 8 September 2017 Roche announces progress in biomarker science in cancer immunotherapy at the European Society for Medical Oncology Congress Roche announced today that the first data on a novel blood-based assay, co-developed with Foundation Medicine (NASDAQ: FMI), will be presented during the European Society for Medical Oncology (ESMO) ... more
Published on: 7 September 2017 Roche ranked again the most sustainable healthcare company in the Dow Jones Sustainability Indices For the ninth consecutive year, Roche has been recognised as Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry index of the Dow Jones Sustainability ... more
Published on: 6 September 2017 Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer Roche today announced results from the global phase III ALUR study showing that Alecensa® significantly reduced the risk of disease worsening or death (progression-free survival, PFS) by 85% compared ... more
Published on: 31 August 2017 Roche to present new data from its oncology portfolio at the 2017 European Society for Medical Oncology (ESMO) Congress Roche today announced that new results from a number of studies across 18 approved and investigational medicines will be presented during the European Society for Medical Oncology (ESMO) Congress ... more
Published on: 30 August 2017 FDA approves Roche’s Actemra/RoActemra (tocilizumab) for the treatment of CAR T cell-induced cytokine release syndrome Roche announced today that the US Food and Drug Administration (FDA) has approved Actemra/RoActemra® (tocilizumab) intravenous injection for the treatment of chimeric antigen receptor (CAR) T ... more
Published on: 24 August 2017 FDA grants Priority Review to Roche’s emicizumab for haemophilia A with inhibitors Roche today announced that the US Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) and granted Priority Review for emicizumab prophylaxis ... more
Published on: 27 July 2017 Roche reports strong performance in the first half of 2017 Group sales increase 5% at constant exchange rates and in Swiss francs more
Published on: 21 July 2017 Roche gains positive CHMP opinion for Actemra / RoActemra in giant cell arteritis Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of Actemra®/RoActemra® (tocilizumab) for the treatment of ... more
Published on: 21 July 2017 CHMP recommends EU approval of Roche’s Gazyvaro for people with previously untreated advanced follicular lymphoma Roche announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Gazyvaro® (obinutuzumab) in combination with chemotherapy, followed by ... more
Published on: 21 July 2017 CHMP recommends EU approval for Roche’s TECENTRIQ (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer Roche today announced that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for TECENTRIQ® (atezolizumab) as a monotherapy for the treatment of adults with ... more
Published on: 17 July 2017 Roche’s OCREVUS (ocrelizumab) approved for relapsing and primary progressive multiple sclerosis in Australia Roche announced today that OCREVUS® (ocrelizumab) has been approved by the Australian Therapeutic Goods Administration (TGA) for the treatment of relapsing forms of multiple sclerosis (RMS) and ... more
Published on: 10 July 2017 Positive phase III results for Roche’s emicizumab in haemophilia A published in The New England Journal of Medicine Roche today announced that data from HAVEN 1, a phase III study evaluating once-weekly subcutaneous emicizumab prophylaxis (preventative) in adults and adolescents with haemophilia A with inhibitors, ... more
Published on: 3 July 2017 Roche expands cobas Liat PCR System menu with launch of cobas MRSA/SA test to target healthcare-associated infections Roche announced today the CE-IVD launch of the cobas® MRSA/SA nucleic acid test for use on the cobas® Liat® System for the qualitative detection and differentiation of methicillin-resistant ... more
Published on: 30 June 2017 Roche acquires mySugr to form a leading open platform for digital diabetes management Roche and mySugr announced today that the two partners have signed an agreement under which Roche acquired all shares of mySugr GmbH. more
Published on: 27 June 2017 Fewer pills, more flexibility in dosing: Roche’s new Esbriet tablet formulation approved in Europe for mild to moderate idiopathic pulmonary fibrosis (IPF) Roche today announced that the European Commission (EC) has approved a new tablet formulation of Esbriet® (pirfenidone) for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF), a ... more
Published on: 26 June 2017 Roche’s emicizumab showed positive results in phase III studies (HAVEN 1 and HAVEN 2) in haemophilia A with inhibitors Roche today announced positive data from the primary analysis of the phase III HAVEN 1 study in adults and adolescents and interim analysis of the phase III HAVEN 2 study in children evaluating ... more
Published on: 23 June 2017 Presentation confirms Venclexta/Venclyxto monotherapy benefit in certain patients with high-risk chronic lymphocytic leukaemia and its potential in other hard-to-treat blood cancers Roche today announced new data from multiple studies of Venclexta®/Venclyxto® (venetoclax), presented at the 22nd European Hematology Association (EHA) Annual Congress, 22-25 June, in Madrid. more
Published on: 23 June 2017 Roche presents new data from GALLIUM study reinforcing clinical benefit of Gazyva/Gazyvaro in people with previously untreated follicular lymphoma Roche announced today that new data from additional analyses of the pivotal phase III GALLIUM study in people with previously untreated follicular lymphoma will be presented at the 22nd European ... more
Published on: 23 June 2017 New data at EAN show Roche’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary progressive multiple sclerosis Roche announced today that new post-hoc analyses from the OCREVUS™ (ocrelizumab) Phase III clinical trial programme in people with relapsing and primary progressive forms of multiple sclerosis (RMS ... more
Published on: 23 June 2017 FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers Roche announced today that the US Food and Drug Administration (FDA) approved Rituxan Hycela™ (rituximab and hyaluronidase human) for subcutaneous (under the skin) injection, for the treatment of ... more
Published on: 14 June 2017 Roche’s employee-driven philanthropic campaign sets new record Today, Roche employees from 145 company sites in 70 countries participate in the 14th Roche Children’s Walk. more
Published on: 5 June 2017 Phase III study showed Roche’s Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer Roche today announced that the phase III ALEX study showed Alecensa® (alectinib) significantly reduced the risk of disease worsening or death (progression-free survival, PFS) by more than half (53%) ... more
Published on: 5 June 2017 APHINITY study shows Roche’s Perjeta-based regimen reduced the risk of invasive cancer returning compared to Herceptin and chemotherapy in HER2-positive early breast cancer Roche, the Breast International Group (BIG), Breast European Adjuvant Study Team (BrEAST) and Frontier Science Foundation (FS) today announced the Phase III APHINITY study showed adjuvant (after ... more
Published on: 3 June 2017 Roche presents new data for TECENTRIQ® (atezolizumab) and updates from across its cancer immunotherapy development programme at ASCO 2017 Roche today announced that new data for TECENTRIQ and updates from across its extensive cancer immunotherapy clinical development programme will be presented during the American Society of Clinical ... more
Published on: 24 May 2017 New data at ATS add to the body of evidence for Roche’s Esbriet (pirfenidone) in idiopathic pulmonary fibrosis (IPF) Roche today announced new retrospective data analyses for Esbriet® (pirfenidone) in idiopathic pulmonary fibrosis (IPF) that were presented at the American Thoracic Society (ATS) 2017 International ... more
Published on: 23 May 2017 FDA approves Roche’s Actemra/RoActemra (tocilizumab) for giant cell arteritis Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Actemra®/RoActemra® (tocilizumab) ) subcutaneous injection for the treatment of GCA, a chronic and severe ... more
Published on: 11 May 2017 Roche to present new data on personalised medicines and cancer immunotherapies at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting Roche today announced new data on 20 approved and investigational medicines will be presented during the American Society of Clinical Oncology (ASCO) Annual Meeting from 2 June to 6 June in Chicago, ... more
Published on: 10 May 2017 Roche provides update on phase III study of TECENTRIQ® (atezolizumab) in people with previously treated advanced bladder cancer Roche today announced that the Phase III IMvigor211 study that evaluated TECENTRIQ® (atezolizumab) in people with locally advanced or metastatic urothelial cancer (mUC) whose disease progressed ... more
Published on: 8 May 2017 Roche launches AVENIO ctDNA Analysis Kits for Oncology Research Roche today announced the global commercial launch of the AVENIO circulating tumor DNA (ctDNA) Analysis Kits, a portfolio of three next-generation sequencing (NGS) liquid biopsy assay kits for ... more
Published on: 27 April 2017 Roche reports a good start in 2017 Group sales increase 4%1 at constant exchange rates and in Swiss francs. Pharmaceuticals Division sales up 3%, driven mainly by Tecentriq and Perjeta. Diagnostics Division sales grow 6%, primarily ... more
Published on: 26 April 2017 New data at AAN reinforce clinical benefit of Roche's OCREVUS™ (ocrelizumab) for relapsing and primary progressive multiple sclerosis Roche announced today that new data from the OCREVUS™ (ocrelizumab) clinical trial programmes will be presented during the 69th American Academy of Neurology (AAN) Annual Meeting in Boston, ... more
Published on: 19 April 2017 Roche to present new data at AAN reinforcing efficacy and safety of newly FDA-approved OCREVUS™ (ocrelizumab) in two types of multiple sclerosis Roche announced today that new data on OCREVUS™ (ocrelizumab) in people with relapsing forms of multiple sclerosis (RMS) and primary progressive MS (PPMS) will be presented during the 69th American ... more
Published on: 18 April 2017 FDA approves Roche’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States Roche today announced that the US Food and Drug Administration (FDA) approved Lucentis® (ranibizumab injection) 0.3 mg for the monthly treatment of withal forms of diabetic retinopathy. more
Published on: 18 April 2017 FDA grants Roche’s TECENTRIQ® (atezolizumab) accelerated approval as initial treatment for certain people with advanced bladder cancer Roche today announced that the US Food and Drug Administration (FDA) granted accelerated approval to TECENTRIQ® (atezolizumab) for the treatment of people with locally advanced or metastatic ... more
Published on: 17 April 2017 Roche announces positive interim results for emicizumab in phase III study of children with haemophilia A Roche announced today interim results from the phase III HAVEN 2 study evaluating emicizumab prophylaxis in children less than 12 years of age with haemophilia A and inhibitors to factor VIII. more
Published on: 10 April 2017 Phase III study shows Roche’s Alecensa was superior to crizotinib in a specific type of lung cancer Roche today announced that the global, randomised phase III ALEX study met its primary endpoint and showed that Alecensa® (alectinib) as an initial (first-line) treatment significantly reduced the ... more
Published on: 5 April 2017 Improving consistency in the diagnosis of cervical pre-cancers: Roche CINtec Histology test receives FDA clearance Roche today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the CINtec® Histology test. more
Published on: 3 April 2017 Roche launches cobas Liat PCR System with four assays into CE-markets Roche today announced the CE-IVD launch of the cobas® Liat® PCR System with four assays including first 20 minute real-time PCR nucleic acid test to detect Clostridium difficile (C. diff). more
Published on: 3 April 2017 Phase III ALUR study supports the use of Roche’s Alecensa for people with advanced ALK-positive lung cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III ALUR study met its primary endpoint, demonstrating that Alecensa® (alectinib) significantly improved progression-free survival ... more
Published on: 29 March 2017 FDA approves Roche’s OCREVUS™ (ocrelizumab) for relapsing and primary progressive forms of multiple sclerosis Roche announced today that the US Food and Drug Administration (FDA) approved OCREVUS™ (ocrelizumab) as the first and only medicine for both relapsing and primary progressive forms of multiple ... more
Published on: 28 March 2017 Roche announces launch of cobas HPV on the cobas 6800/8800 Systems for cervical cancer screening in markets accepting the CE mark Roche announced today the CE-IVD launch of cobas® HPV for use on the cobas® 6800/8800 Systems for cervical cancer screening. more
Published on: 14 March 2017 Roche Annual General Meeting 2017 Roche announced today that its shareholders approved all proposals of the Board of Directors at its ordinary Annual General Meeting (AGM). more
Published on: 2 March 2017 Phase III APHINITY study shows Roche’s Perjeta® regimen helped people with an aggressive type of early breast cancer live longer without their disease returning compared to Herceptin® and chemotherapy Roche, the Breast International Group (BIG), Breast European Adjuvant Study Team (BrEAST) and Frontier Science Foundation (FS) today announced positive results from the phase III APHINITY study. more
Published on: 21 February 2017 Roche receives EU approval of Alecensa (alectinib) for people with previously treated ALK-positive non-small cell lung cancer Roche announced today that the European Commission has granted a conditional marketing authorisation for Alecensa® (alectinib) as monotherapy for the treatment of adult patients with anaplastic ... more
Published on: 18 February 2017 Phase II study supports potential for Roche’s TECENTRIQ (atezolizumab) plus Avastin (bevacizumab) for people with locally advanced or metastatic renal cell carcinoma Roche today announced encouraging results from the Phase II IMmotion150 study that compared TECENTRIQ® (atezolizumab) plus Avastin® (bevacizumab) and TECENTRIQ monotherapy to sunitinib alone in ... more
Published on: 1 February 2017 Roche reports good results in 2016 Commenting on the Group’s results, Roche CEO Severin Schwan said: «I am pleased that we have again reached all our financial targets while our product portfolio has made significant progress ... more
Published on: 23 January 2017 Roche enters a new era in haematology testing, with the launch of the new cobas m 511 analyser Roche announced today that its new, dedicated haematology testing solution, the cobas m 511 integrated haematology analyser, is now available for countries accepting the CE Mark. more
Published on: 9 January 2017 FDA grants Roche’s cancer immunotherapy TECENTRIQ(atezolizumab) Priority Review in additional type of advanced bladder cancer Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for TECENTRIQ® ... more